Registry collecting data on advanced prostate cancer imaging

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This registry collects real-world data on advanced prostate cancer imaging to evaluate the effectiveness of next-generation imaging (NGI) techniques, such as PET/CT and whole-body MRI, compared to conventional imaging methods. It aims to identify the proportion of patients who benefit from NGI at baseline and assess how imaging influences treatment decisions in clinical practice. The study will also stratify metastatic prostate cancer patients based on imaging results and evaluate survival outcomes related to the imaging pathways used. Data will be gathered from medical records and analyzed to improve understanding of imaging's impact on patient outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Adult male patients (≥18 years with no upper age limit).
2. Histologically proven prostate cancer.
3. Patients who require imaging exploration (conventional, Next-Generation Imaging (NGI), or their combination) at high risk for harbouring metastatic deposits at the hormone-sensitive stage, either at the diagnostic workout of a "naïve" patient or at biochemical relapse/progression after local treatment.
4. Patients who authorize their participation in the study by signing a written informed consent form (ICF).

Exclusion Criteria:

1. Patients participating in other interventional or non-interventional study which requires NGI as a triage test for metastatic assessment.
2. Patients with evidence of any other clinically significant disease or condition which in the opinion of the investigator discourages their participation in the study.
3. Patients who will not be able to complete the study.

Where it's running

• Azienda Ospedaliero-Universitaria Careggi
  Florence, Italy Recruiting
• Fundació Puigvert
  Barcelona, Spain Recruiting
• Hospital de la Santa Creu i Sant Pau
  Barcelona, Spain Recruiting
• Hospital Universitario de Canarias
  San Cristóbal de La Laguna, Spain Recruiting
• Universitair Ziekenhuis Leuven
  Leuven, Belgium Not yet recruiting
• Hospital Center University De Lille
  Lille, France Not yet recruiting

Study contacts

• Study coordinator: Francesco Sanguedolce, MD, PhD
• Email: fsanguedol@fundacio-puigvert.es
• Phone: +34934169100

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• PSMA-targeted therapy with hormone suppression for low-volume metastatic prostate cancer

  This phase II trial tests leuprolide acetate alone versus with 177Lu-PSMA-617 (with or without abiraterone acetate and prednisone) in men with hormone-sensitive, low-volume metastatic prostate cancer.

  Recruiting Phase 2 Mayo Clinic · Rochester, Minnesota · NCT07650240

• Mini-tumors to guide treatment for aggressive prostate cancer

  We will grow tiny, patient-derived mini-tumors in the lab to test which treatments work best for men with aggressive or metastatic prostate cancer.

  Recruiting Maastricht Radiation Oncology · Heerlen, Limburg and 2 other locations · NCT07004582

• Targeted alpha therapy for B7-H3 expressing solid tumors using AKY-2519

  This phase 1b trial tests a radiolabeled drug (AKY-2519) to see if it's safe and tolerable in adults with B7-H3 positive advanced solid tumors, including NSCLC and SCLC, with imaging to help guide use.

  Recruiting at 2 sites Phase 1 Aktis Oncology, Inc. · Miami, Florida and 1 other locations · NCT07887971

• PSMA-guided surgery and tissue-resident T cells in node-positive prostate cancer

  This study tests whether PSMA-guided surgery can help identify and study tissue-resident T cells in prostate cancer that has spread to lymph nodes.

  Recruiting Niguarda Hospital · Milan, Lombardy · NCT07879820

• Predictive factors for response to Lu-177 PSMA therapy in metastatic castration-resistant prostate cancer

  This study tests whether imaging, dose measurements, and blood tests can predict which men with metastatic castration-resistant prostate cancer will respond to Lu-177 PSMA therapy.

  Recruiting Lithuanian University of Health Sciences · Kaunas · NCT07863986

• Salvage high-dose-rate brachytherapy for locally recurrent prostate cancer

  This observational study tests whether salvage HDR brachytherapy can help men with locally recurrent prostate cancer after initial radiotherapy, using advanced imaging and biopsy to guide treatment.

  Recruiting at 8 sites Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic · Benidorm, Alicante and 9 other locations · NCT07860528

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.